peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Annual General Meeting of Hansa Medical rescheduled to May 12, 2011

1 Apr 2011, 14:00
Regulatory information
Hansa Medical has previously announced the Annual General Meeting for 2011 to take place on May 5, 2011. The Board of Directors has decided to reschedule the Annual General Meeting of Hansa Medical to May 12, 2011 at 18:00 in Hörsalen at Scheelevägen 22. Notice of Annual General Meeting with a proposed agenda will be published at the latest on April 13 in Dagens Industri, Post- och Inrikes Tidningar and at the corporate website.

For further information, please contact:

Hansa Medical AB
Emanuel Björne, CEO
Mobile: +46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com

Files


Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, anti-alpha-11 and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.